Dr. Fernando is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1505 Northside Boulevard
Suite 4300
Cumming, GA 30041Phone+1 770-205-1331Fax+1 770-205-8727
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 2000 - 2003- Duke University HospitalResidency, Internal Medicine, 1997 - 2000
Duke University School of MedicineClass of 1997
Certifications & Licensure
GA State Medical License 2005 - 2025
NC State Medical License 1997 - 2006- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2013
Publications & Presentations
PubMed
- 20 citationsMulticenter, randomized, double‐blind phase 2 trial of FOLFIRI with regorafenib or placebo as second‐line therapy for metastatic colorectal cancerHanna K. Sanoff, Richard M. Goldberg, Anastasia Ivanova, Seamus O'Reilly, Samer S. Kasbari
Cancer. 2018-08-01 - 8 citationsA phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.Nan Soon Wong, N. Fernando, Johanna C. Bendell, Michael A. Morse, Gerard C. Blobe
Clinical Colorectal Cancer. 2011-09-01 - 22 citationsA Phase II study of Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in the Treatment of Metastatic Colorectal CancerNan Soon Wong, N. Fernando, Andrew B. Nixon, Stephanie M. Cushman, Mebea Aklilu
Anticancer Research. 2011-01-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
